231 related articles for article (PubMed ID: 20858961)
1. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease.
Wang J; Santa-Maria I; Ho L; Ksiezak-Reding H; Ono K; Teplow DB; Pasinetti GM
J Alzheimers Dis; 2010; 22(2):653-61. PubMed ID: 20858961
[TBL] [Abstract][Full Text] [Related]
2. Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.
Pasinetti GM; Ksiezak-Reding H; Santa-Maria I; Wang J; Ho L
J Neurochem; 2010 Sep; 114(6):1557-68. PubMed ID: 20569300
[TBL] [Abstract][Full Text] [Related]
3. [Neuropathology of tauopathy].
Yoshida M
Brain Nerve; 2013 Dec; 65(12):1445-58. PubMed ID: 24323931
[TBL] [Abstract][Full Text] [Related]
4. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
5. Invited review: Neuropathology of tauopathies: principles and practice.
Kovacs GG
Neuropathol Appl Neurobiol; 2015 Feb; 41(1):3-23. PubMed ID: 25495175
[TBL] [Abstract][Full Text] [Related]
6. Mutations causing neurodegenerative tauopathies.
Goedert M; Jakes R
Biochim Biophys Acta; 2005 Jan; 1739(2-3):240-50. PubMed ID: 15615642
[TBL] [Abstract][Full Text] [Related]
7. The neuropathological spectrum of neurodegenerative tauopathies.
Tolnay M; Probst A
IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
[TBL] [Abstract][Full Text] [Related]
8. Neurodegenerative tauopathies.
Lee VM; Goedert M; Trojanowski JQ
Annu Rev Neurosci; 2001; 24():1121-59. PubMed ID: 11520930
[TBL] [Abstract][Full Text] [Related]
9. Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols.
Ksiezak-Reding H; Ho L; Santa-Maria I; Diaz-Ruiz C; Wang J; Pasinetti GM
Neurobiol Aging; 2012 Jul; 33(7):1427-39. PubMed ID: 21196065
[TBL] [Abstract][Full Text] [Related]
10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
[TBL] [Abstract][Full Text] [Related]
11. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains.
Feuillette S; Deramecourt V; Laquerriere A; Duyckaerts C; Delisle MB; Maurage CA; Blum D; Buée L; Frébourg T; Campion D; Lecourtois M
Brain Res; 2010 Jul; 1345():182-9. PubMed ID: 20460118
[TBL] [Abstract][Full Text] [Related]
12. Decrease of the immunophilin FKBP52 accumulation in human brains of Alzheimer's disease and FTDP-17.
Giustiniani J; Sineus M; Sardin E; Dounane O; Panchal M; Sazdovitch V; Duyckaerts C; Chambraud B; Baulieu EE
J Alzheimers Dis; 2012; 29(2):471-83. PubMed ID: 22233767
[TBL] [Abstract][Full Text] [Related]
13. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
[TBL] [Abstract][Full Text] [Related]
15. Tau protein and neurodegeneration.
Goedert M
Semin Cell Dev Biol; 2004 Feb; 15(1):45-9. PubMed ID: 15036206
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.
Rockenstein E; Ubhi K; Mante M; Florio J; Adame A; Winter S; Brandstaetter H; Meier D; Masliah E
BMC Neurosci; 2015 Nov; 16():85. PubMed ID: 26611895
[TBL] [Abstract][Full Text] [Related]
17. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy.
Santa-Maria I; Diaz-Ruiz C; Ksiezak-Reding H; Chen A; Ho L; Wang J; Pasinetti GM
Neurobiol Aging; 2012 Sep; 33(9):2072-81. PubMed ID: 22054871
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.
Schindowski K; Bretteville A; Leroy K; Bégard S; Brion JP; Hamdane M; Buée L
Am J Pathol; 2006 Aug; 169(2):599-616. PubMed ID: 16877359
[TBL] [Abstract][Full Text] [Related]
19. Anti-tau phospho-specific Ser262 antibody recognizes a variety of abnormal hyper-phosphorylated tau deposits in tauopathies including Pick bodies and argyrophilic grains.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):658-64. PubMed ID: 12410387
[TBL] [Abstract][Full Text] [Related]
20. Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies.
Ferrer I; Hernández I; Boada M; Llorente A; Rey MJ; Cardozo A; Ezquerra M; Puig B
Acta Neuropathol; 2003 Nov; 106(5):419-35. PubMed ID: 12955398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
